Teriparatide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •2 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
Rodent carcinogenicity studies showed dose-dependent osteosarcoma with near-lifetime teriparatide exposure. After 18 years of post-marketing surveillance showing no increased risk in humans, the FDA removed the boxed warning and 2-year treatment limit in November 2020.
Transient serum calcium elevations in approximately 11% of patients. Usually asymptomatic and resolving within 16 hours. Monitor serum calcium, especially with concomitant digoxin or thiazide therapy.
⚠️Important Warnings
- •Osteosarcoma risk (historical): Boxed warning removed 2020. Still contraindicated in patients at increased risk for osteosarcoma (Paget disease, unexplained elevated ALP, open epiphyses, prior skeletal radiation).
- •Hypercalcemia: Transient calcium elevation in approximately 11% of patients. Monitor serum calcium. Use caution with digoxin or thiazide diuretics.
- •Orthostatic hypotension: May occur within hours of injection. Administer where patient can sit or lie down if symptoms develop.
- •Pregnancy: Category C. May cause fetal harm. Use effective contraception.
- •Urolithiasis: Teriparatide may increase urinary calcium excretion. Use caution in patients with active or recent urolithiasis.
- •Hyperuricemia: Teriparatide may increase serum uric acid. Monitor in patients with history of gout.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Prescription | FDA-approved as Forteo in November 2002 for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. Osteosarcoma boxed warning removed November 2020. Biosimilars approved. Prescription only; not a controlled substance. |
| European Union | Prescription | Approved by EMA. Available as Forsteo (Eli Lilly) and biosimilars across EU member states. Indicated for osteoporosis in postmenopausal women and men at high fracture risk, and GIO. |
| United Kingdom | Prescription | Approved by MHRA. Available via NHS for severe osteoporosis meeting specific criteria. NICE guidance available. |
| Canada | Prescription | Approved by Health Canada as Forteo for osteoporosis. Available by prescription. |
| Japan | Prescription | Approved as Forteo and Teribone. Both daily and weekly formulations available in Japan. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 80+ community reports
View community protocolsCritical Safety Information#
Teriparatide (Forteo) is an FDA-approved prescription medication with the longest safety track record of any osteoanabolic agent (approved November 2002). The safety profile is well characterized through the Fracture Prevention Trial, the GIO trial, the VERO trial, 18 years of post-marketing osteosarcoma surveillance, and global clinical experience since 2002.
Osteosarcoma: Historical Concern, Resolved#
Preclinical Background#
In Fischer 344 rats, teriparatide at doses 3-60x the human dose administered over near-lifetime durations (2 years in rats, equivalent to most of a rat lifespan) caused dose-dependent increases in osteosarcoma. This finding led to the original 2002 boxed warning and the 2-year cumulative treatment duration limitation.
Why Rats Are Not Humans#
The rat osteosarcoma finding has limited human relevance because:
- Rats have continuous skeletal growth throughout life (no closure of growth plates)
- Rat bone lacks osteonal (Haversian) remodeling present in primates and humans
- These species differences result in an exaggerated skeletal response to sustained PTH1R activation in rats
- Primate studies showed no osteosarcoma signal
18-Year Surveillance Resolution#
Eli Lilly conducted a mandated post-marketing surveillance program linking teriparatide pharmacy records to state cancer registries. After 18 years:
- No increased osteosarcoma incidence among teriparatide users
- Observed rates consistent with background population rates
- The FDA removed the boxed warning and treatment duration limit in November 2020
This was a landmark regulatory decision that fundamentally changed the clinical use of teriparatide, allowing physicians to extend treatment beyond 2 years when clinically appropriate.
Hypercalcemia#
Teriparatide-induced hypercalcemia is the most clinically relevant ongoing safety consideration. Approximately 11% of patients experience serum calcium above ULN, which is higher than with abaloparatide (3.4%) due to teriparatide's more prolonged R0 receptor binding.
Management:
- Usually transient (peaks at 4-6 hours, resolves by 16 hours post-injection)
- Routine calcium monitoring recommended
- Reduce calcium supplementation if persistent mild hypercalcemia occurs
- Evaluate for other causes if calcium remains elevated at trough (pre-injection)
- Discontinue if symptomatic or severe hypercalcemia develops
Regulatory and Legal Status#
Teriparatide is a prescription medication globally. It is not a controlled substance. Biosimilar versions have improved access and affordability.
| Jurisdiction | Brand Names | Status | Key Notes |
|---|---|---|---|
| United States (FDA) | Forteo, biosimilars | Approved (2002) | Boxed warning removed 2020 |
| European Union (EMA) | Forsteo, biosimilars | Approved | PMO, male OP, GIO |
| United Kingdom (MHRA) | Forsteo | Approved | NICE guidance available |
| Canada | Forteo | Approved | Prescription only |
| Japan | Forteo, Teribone | Approved | Daily and weekly formulations |
| Australia (TGA) | Forteo | Approved | PBS listed for eligible patients |
At-Risk Populations#
Patients at Increased Osteosarcoma Risk#
Despite the boxed warning removal, teriparatide remains contraindicated in patients with Paget disease, unexplained elevated alkaline phosphatase, open epiphyses, or prior skeletal radiation.
Pregnant Women#
Pregnancy Category C. Animal studies suggest potential fetal harm. Women of childbearing potential should use effective contraception.
Patients with Kidney Stones#
Teriparatide may increase urinary calcium excretion. Use with caution in patients with active or recent urolithiasis.
Patients with Gout#
Serum uric acid may increase during teriparatide treatment. Monitor in patients with hyperuricemia or gout history.
Risk Mitigation#
For Prescribers#
- Screen for Paget disease and unexplained ALP elevation
- Check baseline serum calcium and vitamin D
- Plan sequential antiresorptive therapy at treatment initiation
- Monitor serum calcium periodically
- Counsel on orthostatic hypotension precautions
- Consider uric acid monitoring in patients with gout history
For Patients#
- Inject at the same time each day; rotate injection sites
- Sit or lie down if dizziness occurs after injection
- Keep pen refrigerated at all times
- Report persistent nausea, vomiting, constipation, or lethargy (hypercalcemia symptoms)
- Take calcium and vitamin D as directed
- Do not stop treatment abruptly without medical guidance on antiresorptive transition
Related Reading#
Frequently Asked Questions About Teriparatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.